Patents by Inventor Michael John Boyd
Michael John Boyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939782Abstract: A wall-mountable perch includes: a frame including: first horizontal side members; a first cross member connected to each of the first horizontal side members proximate to a respective distal end of each of the first horizontal side members; second horizontal side members connected to the first horizontal side members; a platform connected to the second horizontal side members; a plurality of support arms each having a proximal end connected proximate to a proximal end of the frame, each support arm extending vertically upward from the frame and being configured to be flexible to bend along a respective length of each of the plurality of support arms; tension arms each connected to a respective horizontal side member; and adjusting means for producing tension in the tension arms and for causing a second cross member of the wall-mountable perch to move closer to the platform.Type: GrantFiled: January 20, 2021Date of Patent: March 26, 2024Assignee: AAA Royal Construction LLCInventors: Joseph John Boyd, Michael Aziz Allie
-
Patent number: 11884672Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: GrantFiled: May 13, 2020Date of Patent: January 30, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
-
Publication number: 20230339915Abstract: Novel compounds, compositions, and methods of using and preparing the same, which maybe useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: April 2, 2021Publication date: October 26, 2023Inventors: Simon GIROUX, Michael Philip CLARK, Qing TANG, Philippe Marcel NUHANT, Peter JONES, David MESSERSMITH, Upul Keerthi BANDARAGE, Kevin Michael COTTRELL, Michael Aaron BRODNEY, Gabrielle Simone FLEMING, Jian WANG, Jinwang XU, Kevin Brett DANIEL, Michael John BOYD, Mark A. MORRIS, Nathan D. WAAL, Philip Noel COLLIER, Sarathy KESAVAN, Steven M. RONKIN, Hongbo DENG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ
-
Publication number: 20230265080Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: February 9, 2023Publication date: August 24, 2023Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
-
Publication number: 20230159502Abstract: Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Inventors: Simon GIROUX, Michael Philip CLARK, Michael Aaron BRODNEY, Philippe Marcel NUHANT, Emily Elizabeth ALLEN, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Michael John BOYD, David D. DEININGER, Hu ZHANG, Hongbo DENG, Philip Noel COLLIER, Brad MAXWELL, Nathan D. WAAL, Steven M. RONKIN, Jian WANG, Qing TANG, Gabrielle Simone FLEMING, Peter JONES, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL, Upul Keerthi BANDARAGE
-
Publication number: 20230159580Abstract: Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.Type: ApplicationFiled: April 2, 2021Publication date: May 25, 2023Inventors: Simon GIROUX, Michael John BOYD, Robert Francis FIMOGNARI, Jr., Mariam ZAKY, Ronald Lee GREY, Jr., Jinwang XU, Sarathy KESAVAN, Philippe Marcel NUHANT, Pedro Manuel GARCIA BARRANTES, Peter JONES, Michael Aaron BRODNEY, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ, Kevin Michael COTTRELL
-
Patent number: 11623924Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: GrantFiled: October 4, 2019Date of Patent: April 11, 2023Assignee: Vertex Pharmaceuticals IncorporatedInventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
-
Publication number: 20210179587Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).Type: ApplicationFiled: October 4, 2019Publication date: June 17, 2021Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
-
Publication number: 20200361939Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.Type: ApplicationFiled: May 13, 2020Publication date: November 19, 2020Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Diane BOUCHER, Michael John BOYD, Michael Aaron BRODNEY, Michael Philip CLARK, Veronique DAMAGNEZ, Lev Tyler Dewey FANNING, Robert Francis FIMOGNARI, Gabrielle Simone FLEMING, Kevin James GAGNON, Pedro Manuel GARCIA BARRANTES, Robert Daniel GIACOMETTI, Simon GIROUX, Ronald Lee GREY, Jr., Samantha GUIDO, Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., Peter Jones, Sarathy KESAVAN, Mei-Hsiu LAI, Siying LIU, Adam LOOKER, Brad MAXWELL, John Patrick MAXWELL, Ales MEDEK, Philippe Marcel NUHANT, Kirk Alan OVERHOFF, Setu RODAY, Stefanie ROEPER, Steven M. RONKIN, Rupa SAWANT, Yi SHI, Muna SHRESTHA, Marisa SPOSATO, Kathy STAVROPOULOS, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Qing TANG, Stephen THOMSON, Jinwang XU, Mariam ZAKY
-
Patent number: 10533004Abstract: A method of preparing a compound of Formula (I) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (1): or a pharmaceutically acceptable salt thereof with Compound (2): in the presence of water, an organic solvent, a base, and a transition metal catalyst to generate a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 9, 2017Date of Patent: January 14, 2020Assignee: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Michael John Boyd, David B. Miller, Jr., Valerie Ann Cwynar
-
Patent number: 10301304Abstract: The present invention relates to a compound useful as a selective inhibitor of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: GrantFiled: September 25, 2014Date of Patent: May 28, 2019Assignee: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Michael John Boyd, Alex Aronov, Hardwin O'Dowd, Jeremy Green
-
Patent number: 10273233Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: GrantFiled: November 9, 2017Date of Patent: April 30, 2019Assignee: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
-
Publication number: 20180065962Abstract: A method of preparing a compound of Formula (I) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (1): or a pharmaceutically acceptable salt thereof with Compound (2): in the presence of water, an organic solvent, a base, and a transition metal catalyst to generate a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 9, 2017Publication date: March 8, 2018Inventors: Luc J. Farmer, Michael John Boyd, David B. Miller, JR., Valerie Ann Cwynar
-
Publication number: 20180065963Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.Type: ApplicationFiled: November 9, 2017Publication date: March 8, 2018Inventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
-
Publication number: 20160214980Abstract: The present invention relates to a compound useful as a selective inhibitor of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: ApplicationFiled: September 25, 2014Publication date: July 28, 2016Inventors: Michael John Boyd, Alex Aronov, Hardwin O'Dowd, Jeremy Green
-
Patent number: 9133157Abstract: Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: October 26, 2012Date of Patent: September 15, 2015Assignee: Merck Canada Inc.Inventors: Michael John Boyd, Jean-Francois Chiasson, Sheldon Crane, André Giroux
-
Patent number: 9079834Abstract: Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: October 27, 2011Date of Patent: July 14, 2015Assignee: Merck Canada Inc.Inventors: Michael John Boyd, Carmela Molinaro, Amelie Roy, Vouy-Linh Truong
-
Publication number: 20140303171Abstract: Compounds of Formula I are disclosed: wherein A, R1, R2, R3, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Michael John Boyd, Jean-Francois Chiasson, Sheldon Crane, André Giroux
-
Publication number: 20140018325Abstract: Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: October 27, 2011Publication date: January 16, 2014Inventors: Michael John Boyd, Carmela Molinaro, Amelia Roy, Vouy Linh Truong
